Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.

MGMT promoter methylation Nicoletti staining brain tumor primary spheroid culture propidium iodide radioresistance survival fraction tumor-initiating cells

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
21 10 2021
Historique:
received: 24 09 2021
revised: 12 10 2021
accepted: 16 10 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 13 1 2022
Statut: epublish

Résumé

Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder. Reportedly, DSF in combination with Cu

Identifiants

pubmed: 34827559
pii: biom11111561
doi: 10.3390/biom11111561
pmc: PMC8615869
pii:
doi:

Substances chimiques

Disulfiram TR3MLJ1UAI
Temozolomide YF1K15M17Y

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Genom Data. 2015 Sep 1;5:333-336
pubmed: 26251826
Nat Cell Biol. 2018 Oct;20(10):1203-1214
pubmed: 30202050
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cells. 2021 Feb 28;10(3):
pubmed: 33671083
Am J Psychiatry. 1982 Dec;139(12):1596-8
pubmed: 6293320
Prostate Cancer Prostatic Dis. 2013 Dec;16(4):357-61
pubmed: 23958896
Eur J Cancer Prev. 2014 May;23(3):225-32
pubmed: 23863824
Am J Cancer Res. 2019 Nov 01;9(11):2442-2455
pubmed: 31815045
J Neurol Sci. 2011 Apr 15;303(1-2):95-9
pubmed: 21292280
Mol Cancer Ther. 2004 Sep;3(9):1049-60
pubmed: 15367699
Oncotarget. 2012 Oct;3(10):1112-23
pubmed: 23047041
J Neurooncol. 2019 May;142(3):537-544
pubmed: 30771200
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Biochim Biophys Acta. 2012 Sep;1823(9):1580-93
pubmed: 22387373
Clin Cancer Res. 2016 Aug 1;22(15):3860-75
pubmed: 27006494
Sci Rep. 2018 Apr 3;8(1):5527
pubmed: 29615749
F1000Res. 2018 Nov 15;7:1797
pubmed: 30647912
PLoS One. 2013 Oct 23;8(10):e78130
pubmed: 24194908
Drug Metab Dispos. 2021 Jun;49(6):434-441
pubmed: 33762296
Biochem Biophys Res Commun. 2014 Apr 18;446(4):1010-6
pubmed: 24657266
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cancer Res Treat. 2019 Apr;51(2):696-705
pubmed: 30121967
Front Oncol. 2015 Dec 07;5:275
pubmed: 26697410
J Cell Mol Med. 2018 Jan;22(1):439-451
pubmed: 29148232
Sci Rep. 2020 Mar 30;10(1):5686
pubmed: 32231266
Neuro Oncol. 2017 Aug 1;19(8):1079-1087
pubmed: 28340172
J Nucleic Acids. 2010 Nov 21;2010:543531
pubmed: 21113301
Life Sci. 1991;48(3):291-9
pubmed: 1846931
Arch Med Res. 2012 Apr;43(3):243-7
pubmed: 22564423
Curr Neuropharmacol. 2018;16(5):627-635
pubmed: 28786347
Cancer Chemother Pharmacol. 2021 Feb;87(2):159-172
pubmed: 33426580
Mol Med Rep. 2015 Aug;12(2):2313-22
pubmed: 25937029
Mol Cancer Res. 2013 Dec;11(12):1611-23
pubmed: 24145173
J Neurooncol. 2018 May;138(1):105-111
pubmed: 29374809
Onco Targets Ther. 2020 Oct 20;13:10631-10640
pubmed: 33116640
Cancer Res. 2006 Nov 1;66(21):10425-33
pubmed: 17079463
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Int J Pharm. 2021 Mar 15;597:120250
pubmed: 33486040
Oncotarget. 2012 Oct;3(10):1124-36
pubmed: 23165409
Chem Res Toxicol. 1997 Dec;10(12):1319-24
pubmed: 9437520
Arch Biochem Biophys. 2017 Nov 1;633:23-28
pubmed: 28887129
J Med Chem. 2004 Dec 30;47(27):6914-20
pubmed: 15615540
Daru. 2019 Dec;27(2):853-862
pubmed: 31758497
Neuro Oncol. 2021 Feb 25;23(2):240-250
pubmed: 33130898
J Nucl Med. 2014 May;55(5):845-51
pubmed: 24627433
Biochem Pharmacol. 1986 Oct 1;35(19):3341-7
pubmed: 3021167
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Br J Cancer. 2012 Oct 23;107(9):1488-97
pubmed: 23033007
Neuropharmacology. 1983 Sep;22(9):1159-63
pubmed: 6633826
J Pharmacol Exp Ther. 1993 Jul;266(1):23-32
pubmed: 8392551
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9
pubmed: 23650391
DNA Repair (Amst). 2004 Nov 2;3(11):1389-407
pubmed: 15380096
Carcinogenesis. 2014 Mar;35(3):692-702
pubmed: 24193513
Cancer Res. 2014 Oct 15;74(20):5819-31
pubmed: 25320179
Int J Pharm. 2015 Oct 15;494(1):73-82
pubmed: 26235918
Cell Commun Signal. 2020 Mar 5;18(1):36
pubmed: 32138738
Biochem Pharmacol. 2000 Oct 1;60(7):947-53
pubmed: 10974203
Clin Pharmacol Ther. 1984 Oct;36(4):520-6
pubmed: 6090051
Mol Carcinog. 2016 Nov;55(11):1843-1857
pubmed: 26599461
Acta Biomater. 2018 Mar 1;68:113-124
pubmed: 29294377
Cancers (Basel). 2020 Nov 27;12(12):
pubmed: 33260923
J Toxicol Clin Toxicol. 1999;37(2):217-30
pubmed: 10382557
Cancer Lett. 2015 Dec 1;369(1):86-96
pubmed: 26254539
Int J Radiat Biol. 2007 May;83(5):319-29
pubmed: 17457757
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Neuro Oncol. 2010 Jan;12(1):49-57
pubmed: 20150367
Biochem Pharmacol. 2020 Dec;182:114267
pubmed: 33035509
J Am Chem Soc. 2011 Aug 10;133(31):12229-37
pubmed: 21707094
Neuro Oncol. 2015 Jun;17(6):810-21
pubmed: 25378634
Cells. 2019 Sep 13;8(9):
pubmed: 31540259
Front Immunol. 2019 Mar 12;10:407
pubmed: 30930892

Auteurs

Lisa Zirjacks (L)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Nicolai Stransky (N)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Lukas Klumpp (L)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Lukas Prause (L)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Franziska Eckert (F)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Daniel Zips (D)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Sabine Schleicher (S)

Department of Hematology and Oncology, University Hospital Tuebingen, Children's Hospital, 72076 Tuebingen, Germany.

Rupert Handgretinger (R)

Department of Hematology and Oncology, University Hospital Tuebingen, Children's Hospital, 72076 Tuebingen, Germany.

Stephan M Huber (SM)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Katrin Ganser (K)

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tübingen, Germany.

Articles similaires

Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans
Humans Temozolomide RNA, Long Noncoding Glioblastoma Drug Resistance, Neoplasm
Humans Monocarboxylic Acid Transporters Glioblastoma Cell Movement Cell Proliferation
1.00
Glioblastoma Humans Lipid Droplets Macrophages Tumor Microenvironment

Classifications MeSH